Trading at a very low 13.77 P/E ratio. Short interest is quiet high at 9.15%, which could ignite a rally. Bristol-Myers Squibb resumed with Buy rating and $60 (16% upside) price target at BofAML. Company profile Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.